<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02538003</url>
  </required_header>
  <id_info>
    <org_study_id>LCB01-0371-13-1-03</org_study_id>
    <nct_id>NCT02538003</nct_id>
  </id_info>
  <brief_title>To Evaluate the Effect of Food on Pharmacokinetics(PK), Phase I Clinical Study of LCB01-0371</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, Crossover, Phase Ⅰ Trial to Evaluate the Effect of Food on the Pharmacokinetics of LCB01-0371 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LegoChem Biosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LegoChem Biosciences, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety, tolerability of LCB01-0371 after
      fasting/non-fasting food taken in healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Open-label, Single dose, Crossover, Phase Ⅰ Trial to evaluate the effect of
      food on the pharmacokinetics of LCB01-0371 in healthy male subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse events</measure>
    <time_frame>From date of randomization until follow up after 7 days from last hospital discharge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: AUClast(Area under the plasma concentration)</measure>
    <time_frame>0(predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Cmax(Peak plasma concentration)</measure>
    <time_frame>0(predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1(RT):LCB01-0371 Tablet 800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period:LCB01-0371 Tablet 800mg(Reference: Taken drug before meal)
Period: LCB01-0371 Tablet 800 mg(Test: Taken drug after meal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2(TR):LCB01-0371 Tablet 800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period:LCB01-0371 Tablet 800mg(Test:taken drug after meal)
Period: LCB01-0371 Tablet 800 mg(Reference:taken drug before meal)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCB01-0371 Tablet 800 mg(R)</intervention_name>
    <description>Reference: taken drug before meal</description>
    <arm_group_label>Group 1(RT):LCB01-0371 Tablet 800mg</arm_group_label>
    <arm_group_label>Group 2(TR):LCB01-0371 Tablet 800mg</arm_group_label>
    <other_name>LCB01-0371 Tablet 400 mg 2 Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCB01-0371 Tablet 800 mg(T)</intervention_name>
    <description>Test: taken drug after meal</description>
    <arm_group_label>Group 1(RT):LCB01-0371 Tablet 800mg</arm_group_label>
    <arm_group_label>Group 2(TR):LCB01-0371 Tablet 800mg</arm_group_label>
    <other_name>LCB01-0371 Tablet 400 mg 2 Tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male between 20 and 40 years of age at the time of screening with body mass
             index (BMI) between 19 kg/m2 and 28 kg/m2 at the time of screening

          2. Appropriated for a medical examination by interview,Vital sign,physical examination,
             local laboratory test result and 12-lead ECG

          3. Capable of performing follow up visit, blood sampling

          4. Agree to continue to use a medically reliable dual contraception and not to donate
             sperm in this protocol for the duration of the study and for 28 days after last dose
             of investigational product

          5. Capable of giving written informed consent, willing to participate in this clinical
             trial, and willing to comply with all study requirements

        Exclusion Criteria:

          1. History of clinically significant disease such as digestive system, respiratory,
             musculoskeletal, cardiovascular, endocrine, neuropsychiatry, hematology,
             cardiovascular system

          2. History of gastrointestinal problem (e.g. Crohn's disease, gastro-intestinal ulcer)
             within 180 days possibly affecting absorption of clinical trial drugs, or history of
             surgery (except simple appendectomy and herniotomy)

          3. History of hypersensitivity reaction or history of clinically significant
             hypersensitivity reaction to LCB01-0371 or same class of the study drugs (linezolid)
             or other drugs including aspirin and antibiotics(except non active allergic rhinitis)

          4. History of drug abuse or positive result at urine drug screening test at screening
             visit

          5. Intake drug which expected to chronic influence of drug absorption or elimination
             within 30 days prior to screening visit

          6. Other: Patients considered unable perform for the study by the investigator concerning
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaeyong Chung, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Bundang</city>
        <state>Gyeonggi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2015</study_first_submitted>
  <study_first_submitted_qc>September 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2015</study_first_posted>
  <last_update_submitted>March 22, 2016</last_update_submitted>
  <last_update_submitted_qc>March 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

